- Home
- CLPS vs BOLD Comparison
CLPS vs BOLD Comparison
Compare CLPS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPS
- BOLD
- Stock Information
- Founded
- CLPS 2005
- BOLD 2018
- Country
- CLPS Hong Kong
- BOLD United States
- Employees
- CLPS N/A
- BOLD N/A
- Industry
- CLPS Computer Software: Prepackaged Software
- BOLD
- Sector
- CLPS Technology
- BOLD
- Exchange
- CLPS Nasdaq
- BOLD Nasdaq
- Market Cap
- CLPS 32.7M
- BOLD 30.3M
- IPO Year
- CLPS 2018
- BOLD 2024
- Fundamental
- Price
- CLPS $1.02
- BOLD $1.42
- Analyst Decision
- CLPS
- BOLD Buy
- Analyst Count
- CLPS 0
- BOLD 3
- Target Price
- CLPS N/A
- BOLD $22.50
- AVG Volume (30 Days)
- CLPS 14.3K
- BOLD 69.6K
- Earning Date
- CLPS 03-05-2025
- BOLD 05-12-2025
- Dividend Yield
- CLPS 12.74%
- BOLD N/A
- EPS Growth
- CLPS N/A
- BOLD N/A
- EPS
- CLPS N/A
- BOLD N/A
- Revenue
- CLPS $153,816,045.00
- BOLD N/A
- Revenue This Year
- CLPS N/A
- BOLD N/A
- Revenue Next Year
- CLPS N/A
- BOLD N/A
- P/E Ratio
- CLPS N/A
- BOLD N/A
- Revenue Growth
- CLPS 5.81
- BOLD N/A
- 52 Week Low
- CLPS $0.68
- BOLD $1.06
- 52 Week High
- CLPS $1.70
- BOLD $12.65
- Technical
- Relative Strength Index (RSI)
- CLPS 43.61
- BOLD N/A
- Support Level
- CLPS $0.95
- BOLD N/A
- Resistance Level
- CLPS $1.11
- BOLD N/A
- Average True Range (ATR)
- CLPS 0.09
- BOLD 0.00
- MACD
- CLPS -0.01
- BOLD 0.00
- Stochastic Oscillator
- CLPS 30.61
- BOLD 0.00
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.